CureMatch Co-Founder and Colleagues to Present 11 Abstracts at Prestigious ASCO 2017 Conference

Saturday, June 3, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

Many of these precision oncology findings have been incorporated into the intelligence of the CureMatch decision support platform

CHICAGO, June 2, 2017 /PRNewswire/ -- UCSD oncologist and CureMatch Co-Founder Dr. Razelle

Kurzrock and colleagues are presenting ground-breaking cancer discoveries on a variety of topics related to personalized cancer therapy at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The Annual Meeting brings together oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.

The abstracts cover a broad range of topics in precision oncology, including combination therapy, targeted therapy, immunotherapy, liquid biopsies, next-generation DNA sequencing, RNA expression, and other topics that are highly relevant to CureMatch. The abstracts explore a broad range of cancers.

"We are very proud of Dr. Kurzrock and her team for what they have accomplished," said Stephane Richard, Ph.D., President and COO of CureMatch, who will also be attending the ASCO conference. "Together, these abstracts further strengthen the case for the use of precision medicine in cancer treatment. CureMatch's decision support platform incorporates many of the findings from these studies in its custom-curated databases, so many of these discoveries are available to oncologists and their patients today."

Dr. Kurzrock is a board-certified medical oncologist and a renowned expert in precision medicine. She is the Director of the Center for Personalized Cancer Therapy at the Moores Cancer Center at University of California, San Diego, and is a Co-Founder and Chief Medical Advisor of CureMatch.

The following is a list of the abstracts that are co-authored by Dr. Kurzrock including dates and locations of the presentations:

Matched Combination Therapy

Abstract 2512 – Personalized, molecularly matched combination therapies for treatment. Hall A, June 5, 8:00 AM to 11:30 AM.

Advances in Precision Medicine

Abstract 6086 – Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway.  Hall A, June 5, 1:15 PM to 4:45 PM.

Abstract 9073 – Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway. Hall A, June 3, 8:00 AM to 11:30 AM.

Abstract 2513 – Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson precision medicine study. Hall A, June 5, 8:00 AM to 11:30 AM.

Abstract TPS11625 – WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. Hall A, June 3, 1:15 PM to 4:45 PM.

Circulating Tumor DNA

Abstract 1514 – Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing. Hall A, June 5, 1:15 PM to 4:45 PM.

Abstract 11511 – Genomic analysis of circulating tumor DNA in 442 patients with carcinoma of unknown primary: Implications for targeted therapeutics. S406, June 3, 4:45 PM to 6:00 PM.

Abstract 11593 – Genomic alterations in 670 patients with diverse cancers analyzed by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). Hall A, June 3, 1:15 PM to 4:45 PM.

Abstract 11574 – The mutational landscape of gastrointestinal malignancies as reflected by circulating tumor DNA. Hall A, June 3, 1:15 PM to 4:45 PM.

Tumor Biology

Abstract 11578 – Rare tumor clinic: The UCSD Moores Cancer Center experience with a precision therapy approach. Hall A, June 3, 1:15 PM to 4:45 PM.

Developmental Therapeutics

Abstract 2526 – Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers. Hall A, June 5, 8:00 AM to 11:30 AM.

Abstract 2563 – Pharmaco-kinetics/dynamics (PK/PD) evaluation and individual patient cross-over studies with growth trajectory assessment to adaptively develop ilorasertib. Hall A, June 5, 8:00 AM to 11:30 AM.

The abstracts were authored by Dr. Kurzrock and collaborators from several institutions. Additional information about ASCO 2017 can be found at

About CureMatch

CureMatch™, Inc., based in San Diego, is a digital health company focused on personalized medicine and combination therapy in oncology. Combination therapy has been used effectively in the treatment of other diseases, such as HIV/AIDS, and is considered by many to be the future of cancer treatment. CureMatch's report guides oncologists in the selection of combinations of cancer drugs that are personalized for individual patients, based on the molecular profile of the patient's own tumor. The CureMatch technology has a foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit


To view the original version on PR Newswire, visit:

SOURCE CureMatch

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store